Pharmaceutical

STAT+: Philips pays $2.4 million for allegedly giving k...

Philips Respironics paid $2.4 million to settle allegations that it gave free ma...

STAT+: Cytokinetics heart drug aficamten succeeds in pi...

Cytokinetics heart drug aficamten succeeds in pivotal study.

STAT+: What comes after Wegovy? The quest to eradicate ...

The companies that started an obesity revolution with drugs like Wegovy and Zepb...

Opinion: Remembering Betty Rollin, who told her breast ...

Patient advocate Betty Rollin died as she lived: on her own terms.

Violet CEO on measuring clinician inclusiveness: ‘It’s ...

Violet trains clinicians on identity-centered health care, particularly for pati...

STAT+: 3 FDA staffers to watch in 2024

The FDA has a lot on its plate in 2024 with the reorganizations of its food cent...

Opinion: People with food insecurity deserve better nut...

Food literacy skills and nutrition knowledge make a lifelong impact in improving...

STAT+: 3 issues to watch in pharma in 2024

What are the issues to watch in pharma in 2024? The past is likely prologue.

STAT+: Complications spiked 25% in hospitals bought by ...

Adverse events at hospitals like falls and infections spiked 25% after private e...

Opinion: Does food as medicine help patients with diabe...

Does food as medicine help patients with diabetes? Here’s what a new clinical tr...

STAT+: With Biden finalizing an Apple Watch ban, Apple ...

President Biden finalized an import ban of latest Apple Watches after the ITC de...

STAT+: Bristol Myers will pay $4.1 billion for cancer s...

Bristol Myers Squibb will pay $4.1 billion for RayzeBio, buying into the fast-gr...

STAT+: New weight loss drugs have proven their effectiv...

A team of researchers will soon launch a study driven by a pressing question in ...

STAT+: 3 CRISPR advances to watch in 2024

Approval of the first CRISPR-based medicine paves the way for in vivo therapies,...

STAT+: 3 medtech trends to watch in 2024

STAT looks at the forces that shaped the medical devices industry last year, and...

AZD-9550 by AstraZeneca for Metabolic Dysfunction-Assoc...

AZD-9550 is under clinical development by AstraZeneca and currently in Phase I f...